VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
09/20/2021 - 08:00 AM
BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference , to take place September 27th – 30th .
The presentation will take the form of a fireside chat, which will be archived here for 90 days. Management will also be available for 1-on-1 meetings with investors.
About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes Phase 3 ready FCD105 (3% minocycline and 0.3% adapalene) for the treatment of moderate-to-severe acne vulgaris, FMX114 for the treatment of mild-to-moderate atopic dermatitis and a library of bromodomain & extra-terminal domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases. VYNE has received FDA approval for AMZEEQ® (minocycline) topical foam, 4% , the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5% , the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com .
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations: jallaire@lifesciadvisors.com
Tyler ZerondaTyler.Zeronda@vynetx.com
VYNE Rankings
N/A Ranked by Stock Gains
VYNE Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About VYNE
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.
